Composition containing ultraviolet wavelength conversion material

Abstract

To provide compositions suitable for novel cell activation.SOLUTION: There is provided a composition containing an ultraviolet wavelength-converting substance, a dispersant, an ultraviolet absorber and / or ultraviolet scatterer, and oil, the amount of the dispersant compounded being 1 wt.% or more.SELECTED DRAWING: Figure 5

Description

[Technical Field]

[0001] The present invention relates to a composition containing an ultraviolet wavelength converting substance, which has a cell activating effect. [Background technology]

[0002] Ultraviolet rays are believed to generate free radicals in the body, causing sebum oxidation and damage to cellular DNA. The harmful effects of ultraviolet rays on the skin include skin cancer, photoaging, age spots, wrinkles, and inflammation, making them undesirable from the perspectives of health and beauty. While ultraviolet rays are used for their sterilizing effects, considering the balance with the harmful effects of ultraviolet rays, the current focus is on defense rather than proactive use of ultraviolet rays.

[0003] Therefore, many measures are taken to protect the skin from UV rays, such as using sunscreen, staying indoors to avoid exposure to sunlight, using UV-blocking hats and clothing, and using UV-blocking film.

[0004] For example, Patent Document 11 describes an oil-based fluorescent cosmetic containing fluorescent zinc oxide in its examples, but the concentration of the dispersant is low at 0.8%, and there is no mention of an ultraviolet wavelength conversion substance to achieve a cell activation effect. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Patent No. 6424656 [Patent Document 2] Patent No. 6361416 [Patent Document 3] International Publication No. 2018 / 004006 [Patent Document 4] Japanese Patent Application Publication No. 2018-131422 [Patent Document 5] Japanese Patent Application Publication No. 5-117127 [Patent Document 6] Patent No. 4048420 [Patent Document 7] Patent No. 4677250 [Patent Document 8] Patent No. 3303942 [Patent Document 9] Japanese Patent Application Laid-Open No. 2017-88719 [Patent Document 10] International Publication No. 2018 / 117117 [Patent Document 11] Japanese Patent Application Publication No. 2017-122076 Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a novel composition having a cell activation effect using ultraviolet light. [Means for solving the problem]

[0007] The present inventors have conducted extensive research into how ultraviolet light can be effectively used on the skin, and as a result have come up with the idea of ​​a composition containing an ultraviolet wavelength converting substance that has excellent cell activation effects.

[0008] The present application provides the following inventions. (1) A composition comprising (A) an ultraviolet wavelength conversion substance, (B) a dispersant, (C) an ultraviolet absorber and / or an ultraviolet scattering agent, and (D) an oil component, wherein the blending amount of the (B) dispersant is 1 mass% or more. (2) The composition according to (1), wherein the (A) ultraviolet wavelength conversion material is an inorganic ultraviolet wavelength conversion material. (3) The composition according to (2), wherein the inorganic ultraviolet wavelength conversion material is a zinc oxide phosphor or a magnesium titanate phosphor. (4) The composition according to (1), wherein the (A) ultraviolet wavelength conversion material is an organic ultraviolet wavelength conversion material. (5) The composition according to (4), wherein the organic ultraviolet wavelength conversion substance is phycocyanin. (6) The composition according to any one of (1) to (4), wherein the (A) ultraviolet wavelength conversion material contains both an inorganic ultraviolet wavelength conversion material and an organic ultraviolet wavelength conversion material. (7) The composition according to any one of (1) to (6), wherein the (B) dispersant is one or more selected from the group consisting of PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-polydimethylpolysiloxane ethyl dimethicone, lauryl PEG-polydimethylpolysiloxane ethyl dimethicone, cetyl PEG / PPG-10 / dimethicone, isostearic acid, polyglyceryl-2 diisostearate, carboxydecyltrisiloxane, PEG-12 dimethicone, and polyoxyethylene sorbitan monostearate. (8) The composition according to any one of (1) to (7), which contains one or more kinds of powder selected from the group consisting of polymethyl methacrylate, silica, talc, starch, and polyurethane. (9) The composition according to any one of (1) to (8), which is a water-in-oil composition. (10) The composition according to any one of (1) to (9), which is a sunscreen cosmetic. (11) The composition according to any one of (1) to (10), which exhibits a fluorescence intensity enhancing effect. (12) The composition according to any one of (1) to (11), which exhibits a cell-activating effect. [Effects of the Invention]

[0009] The ultraviolet wavelength conversion substance of the present invention is suitable for effectively utilizing ultraviolet rays to activate skin cells and can exert a favorable effect on the skin, and the component composition of the composition of the present invention is suitable for the ultraviolet wavelength conversion substance to convert ultraviolet rays into visible light (fluorescence). Conventionally, because ultraviolet rays are not good for the skin, it has been common technical knowledge in the field to take measures to minimize exposure to ultraviolet rays. However, the present invention is based on the discovery that ultraviolet wavelength conversion substances conversely utilize ultraviolet rays to activate cells, thereby exerting a favorable effect on the skin, which is quite surprising. Therefore, the composition of the present invention may lead to an improvement in quality of life, such as encouraging people who have previously avoided ultraviolet rays as much as possible for beauty or health reasons to go outside more often. [Brief explanation of the drawings]

[0010] [Figure 1] Figure 1 shows a schematic diagram of Experiments 1 and 2. [Figure 2] Figure 2 shows the cell activity upon UV irradiation using each ultraviolet light in Experiment 1. The vertical axis shows the relative fluorescence intensity (au). [Figure 3] Figure 3 shows the cellular activity in Experiment 2 when irradiated with UV light of various intensities using various concentrations of C-phycocyanin, as expressed as relative fluorescence intensity (au). [Figure 4] Figure 4 is a schematic diagram of Experiment 3. [Figure 5] Figure 5 shows the relative fluorescence intensity (au) of cells whose cell activity was once reduced in Experiment 3 when they were irradiated with UV using C-phycocyanin (P test). DETAILED DESCRIPTION OF THE INVENTION

[0011] The present invention will be described in detail below with reference to specific embodiments, but the present invention is not limited to the following embodiments and can be embodied in any form without departing from the spirit of the present invention.

[0012] All patent publications, published patent applications, non-patent publications, and other documents cited in this disclosure are hereby incorporated by reference in their entirety into this disclosure for all purposes.

[0013] In this disclosure, when applied to a numerical value, the symbol "to" refers to a range of values ​​that is equal to or greater than the specified reference value and is equal to or less than the specified reference value.

[0014] (A) UV wavelength conversion material The composition of the present invention contains an ultraviolet wavelength conversion substance as an active ingredient. The ultraviolet wavelength conversion substance refers to a substance that converts the wavelength of ultraviolet rays contained in incident light and emits outgoing light with a wavelength longer than that of the ultraviolet rays.

[0015] The ultraviolet light may include UVA, UVB, UVC, etc. In one embodiment, the ultraviolet light is light having a peak wavelength between 200 nm and 400 nm. Alternatively, the ultraviolet light may be contained in incident light, such as sunlight. Alternatively, the incident light may be ultraviolet light, or artificially generated ultraviolet light may be used.

[0016] The emitted light from the ultraviolet wavelength conversion material has a wavelength longer than that of ultraviolet light, preferably having a peak wavelength between 500 nm and 700 nm. The emitted light may have one or more peaks at, for example, but not limited to, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, or any range of these values, or may be red light, orange light, green light, blue light, etc. In one embodiment, the ultraviolet wavelength conversion material emits light with a dominant wavelength of 500 nm to 700 nm when excited with excitation light of 200 nm to 400 nm.

[0017] Examples of ultraviolet wavelength conversion substances include the following: phycobiliproteins such as allophycocyanin, C-phycocyanin (e.g., LinaBlue), R-phycocyanin, phycoerythrocyanin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin; natural or synthetic ingredients such as vitamin A, beta-carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, lycopene, gardenia, safflower, turmeric, cochineal, perilla, red cabbage, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins, and polyphenols; and Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205 P, Yellow No. 4, Yellow No. 5, Green No. 201, pyranine concentrate, Blue No. 1, and 2,4-diaminophenol hydrochloride. Examples of suitable phosphors include pigments such as xyethanol, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringbone Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, Red No. 104, and meta-aminophenol; phosphors obtained by doping inorganic compounds to give them fluorescence, such as the blue phosphor containing amorphous silica particles, cerium, phosphorus, and / or magnesium described in Japanese Patent No. 6424656, and the red phosphor containing a europium-activated compound of a mixed crystal of an alkaline earth metal sulfide and a gallium compound described in Japanese Patent No. 6361416, zinc oxide phosphors described in International Publication No. 2018 / 004006, zinc oxide phosphors described in Japanese Patent Application Publication No. 2018-131422, and inorganic phosphors described in Japanese Patent Application Publication No. 5-117127 (hereinafter, phosphors derived from zinc oxide are referred to as "zinc oxide phosphors"; for example, Lumate G). In one embodiment, the inorganic phosphor is ZnO:Zn, Zn 1+z ,ZnO 1-xThe phosphor is one or more phosphors selected from phosphors described in WO 2018 / 004006 in which zinc oxide, which can be expressed as follows, is doped with a sulfur-containing compound, for example, a sulfide salt such as zinc sulfide or zinc sulfate and / or a sulfate salt; magnesium titanate phosphors in which magnesium titanate, such as MgTiO3 or Mg2TiO4, is doped with manganese (hereinafter, phosphors derived from magnesium titanate are referred to as "magnesium titanate phosphors"; for example, LumateR); and calcium phosphate phosphors in which calcium phosphate, such as Ca(H2PO4)2, CaHPO4, or Ca3(PO4)2, is doped with cerium.

[0018] Ultraviolet wavelength conversion substances may be obtained by extraction or other methods from natural sources such as animals, plants, and algae, or by artificial methods such as chemical synthesis. For example, phycobiliproteins may be prepared by extracting algae, such as blue-green algae like Spirulina platensis or red algae like Porphyridium purpureum, using methods described in, for example, Patent Nos. 4048420, 4677250, and 3303942. Zinc oxide phosphors may be produced, for example, by methods described in International Publication No. 2018 / 004006, JP 2018-131422, and JP 5-117127. Magnesium titanate phosphors may be produced by methods described in JP 2017-88719. Calcium phosphate phosphors may be produced by methods described in International Publication No. 2018 / 117117.

[0019] These ultraviolet wavelength conversion substances may be composed of or contain the above-exemplified components, and may be used alone or in combination, as long as they do not impair the wavelength conversion effect of the present invention. For example, the above-mentioned phycobiliproteins or inorganic phosphors may be mixed with other ultraviolet wavelength conversion substances, such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.), to achieve a synergistic effect. However, these components are merely examples, and any substance that exhibits the wavelength conversion effect of the present invention can be used.

[0020] Furthermore, the content of the ultraviolet wavelength conversion material in the composition of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be appropriately determined depending on the type of ultraviolet wavelength conversion material and the use of the composition containing the ultraviolet wavelength conversion material. For example, it can be any content within the range of 0.01 to 99.99% by weight, 0.1% to 99.9% by weight, etc.

[0021] In one embodiment of the present invention, the ultraviolet wavelength conversion substance in the composition is a zinc oxide phosphor (e.g., Lumate G), and the content of the zinc oxide phosphor in the composition of the present invention is preferably 0.1 wt % or more, preferably 1.0 wt % or more, more preferably 1.5 wt % or more, and even more preferably 2 wt % or more, and 20 wt % or less, preferably 15 wt % or less, more preferably 10 wt % or less, and even more preferably 5 wt % or less, and is 0.01 to 99.99 wt %, 0.1 to 99.9 wt %, 0.1 to 50 wt %, 0.1 to 40 wt %, 0.1 to 30 wt %, 0.1 to 20 wt %, 0.1 to 10 wt %, or 1 to 10 wt % of the total composition.

[0022] In one embodiment of the present invention, the ultraviolet wavelength conversion substance in the composition is a magnesium titanate oxide phosphor (e.g., Lumate®), and the content of the magnesium titanate phosphor in the composition of the present invention is preferably 0.1 wt % or more, preferably 1.0 wt % or more, more preferably 1.5 wt % or more, even more preferably 2 wt % or more, and 20 wt % or less, preferably 15 wt % or less, more preferably 10 wt % or less, even more preferably 5 wt % or less, and is 0.01 to 99.99 wt %, 0.1 to 99.9 wt %, 0.1 to 50 wt %, 0.1 to 40 wt %, 0.1 to 30 wt %, 0.1 to 20 wt %, 0.1 to 10 wt %, or 1 to 10 wt % of the total composition.

[0023] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the composition is phycocyanin (e.g., LinaBlue). The preferred phycocyanin content in the composition of the present invention is 0.00001% by weight or more, preferably 0.0001% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, and is 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, or 0.0001 to 5% by weight.

[0024] Cell activation includes, but is not limited to, promoting the metabolism and turnover of animal cells, including human cells, such as skin fibroblasts and / or keratinocytes, improving function, promoting proliferation, inhibiting oxidation, improving resistance to fatigue and external stimuli, and inhibiting decline in function and activity. Activating skin cells is expected to have effects such as preventing and improving wrinkles, age spots, skin aging, photoaging, etc.

[0025] The cell activation effect can be measured, for example, as in the examples, by measuring the viability, reducing capacity, and proliferation of live cells using Alamar Blue, or any other method can be used, such as other dye assays, mitochondrial membrane potential-dependent dye assays, intracellular cytochrome c assays, elastase cleavage dye assays, ATP, ADE assays, glycolytic flux, and oxygen consumption assays.

[0026] For example, as in the examples, the fluorescence intensity can be measured by forming a coating film of the composition on the surface of a substrate and irradiating it with ultraviolet light, and then measuring the fluorescence intensity using a spectrofluorometer. The substrate can be a resin substrate such as polymethyl methacrylate (PMMA), nylon, or acrylic plate, or an inorganic plate such as glass or quartz. For example, a PMMA plate with a V-shaped groove on its surface (also known as an "S plate": see Japanese Patent No. 4453995) can be used. The fluorescence intensity can be measured as the fluorescence value at a specific single wavelength, or as the integrated value over a specific wavelength range.

[0027] (B) Dispersant The composition of the present invention contains a dispersant. A dispersant is a substance that can adsorb to the surface of particles dispersed in an aqueous or oily phase, thereby dispersing the particles uniformly in an aqueous or oily medium. The dispersant that can be used in the present invention is not particularly limited as long as it does not impair the function of the ultraviolet wavelength conversion substance, and oil-based dispersants are preferred. Examples of oil-based dispersants include nonionic surfactants, cationic surfactants, anionic surfactants, silicone-based surfactants, and fatty acids. In the present invention, it is particularly preferred to use nonionic surfactants, silicone-based surfactants, and / or fatty acids that are commonly used in cosmetics and pharmaceuticals.

[0028] Preferred dispersing agents for inclusion in the compositions of the present invention include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-polydimethylpolysiloxane ethyl dimethicone, lauryl PEG-polydimethylpolysiloxane ethyl dimethicone, cetyl PEG / PPG-10 / dimethicone, isostearic acid, polyglyceryl-2 diisostearate, carboxydecyltrisiloxane, PEG-12 dimethicone, or polyoxyethylene sorbitan monostearate, or a combination of two or more thereof.

[0029] Preferred examples of the dispersant contained in the composition of the present invention, which enhances the function of the ultraviolet wavelength conversion substance, include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyltrisiloxane, or a combination of two or more of these.

[0030] The content of the dispersant in the composition of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be determined appropriately depending on the type of ultraviolet wavelength conversion substance and the use of the composition containing the ultraviolet wavelength conversion substance. For example, it can be any content within the range of 0.01 to 99.99% by weight, 0.1% to 99.9% by weight, etc.

[0031] The content of the dispersant in the composition of the present invention is preferably 0.1 wt% or more, more preferably more than 0.8%, 0.9% by mass or more, more preferably 1.0% by mass or more, even more preferably 1.5% by mass or more, or 2% by mass or more, and is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, and even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, 1 to 10 wt%, 1.5 to 10 wt%, or 0.8 to 3 wt% of the total composition.

[0032] In one embodiment of the present invention, the dispersant in the composition is PEG-10 dimethicone, and the content of the dispersant in the composition is 0.1 wt% or more, preferably more than 0.8%, 0.9% by mass or more, more preferably 1.0% by mass or more, even more preferably 1.5% by mass or more, or 2% by mass or more, relative to the total composition, and is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, 1 to 10 wt%, 1.5 to 10 wt%, or 0.8 to 3 wt% relative to the total composition.

[0033] In one embodiment of the present invention, the dispersant in the composition is a combination of PEG-10 dimethicone and one or more dispersants selected from the group consisting of bisbutyl dimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, and carboxydecyl trisiloxane, and the content of PEG-10 dimethicone in the composition is 0.1% by weight or more, preferably 1.0% by weight or more, more preferably 1.5% by weight or more, and even more preferably 2% by weight or more, and is 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, and is 0.01 to 99% by weight or less, based on the total composition. 0.99% by weight, 0.1 to 99.9% by weight, 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.1 to 20% by weight, 0.1 to 10% by weight, 0.5 to 10% by weight, 1 to 10% by weight, 1.5 to 10% by weight, or 0.8 to 3% by weight, and the content of each dispersant in the combination is 0.1% by weight or more, preferably 1.0% by weight or more, and more preferably 1.5% by weight or more, based on the total weight of the composition; It is more preferably 2% by weight or more and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, and is 0.1 to 50% by weight, 0.1 to 40% by weight, 0.1 to 30% by weight, 0.1 to 20% by weight, 0.1 to 10% by weight, 0.5 to 10% by weight, 1 to 10% by weight, 1.5 to 10% by weight, or 0.8 to 3% by weight relative to the total composition.

[0034] (C) UV absorber and / or UV scattering agent Ultraviolet absorbers and ultraviolet scattering agents absorb or scatter incident ultraviolet light, and are therefore thought to indirectly inhibit the function of ultraviolet wavelength conversion materials. However, surprisingly, the composition of the present invention can contain ultraviolet absorbers and / or ultraviolet scattering agents, and can exhibit the function of ultraviolet wavelength conversion materials.

[0035] The ultraviolet absorber refers to a substance that absorbs ultraviolet rays, converts them into energy such as heat or infrared rays, and then emits the converted energy. The ultraviolet absorber that can be used in the present invention is not particularly limited as long as it does not directly impair the function of the ultraviolet wavelength conversion substance, and examples thereof include salicylic acid-based ultraviolet absorbers such as homomenthyl salicylate, ethylhexyl salicylate, homosalate, and triethanolamine salicylate; Cinnamic acid-based UV absorbers such as 2-ethylhexyl para-methoxycinnamate, glyceryl di-para-methoxycinnamate mono-2-ethylhexanoate, methyl 2,5-diisopropylcinnamate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine (hereinafter also referred to as "ethylhexyl triazone"), methyl bis(trimethylsiloxy)silylisopentyl trimethoxycinnamate, a mixture of isopropyl para-methoxycinnamate and diisopropyl cinnamate, and diethanolamine p-methoxyhydrocinnamate; benzoylmethane-based ultraviolet absorbers such as 2-phenyl-benzimidazole-5-sulfuric acid, 4-isopropyldibenzoylmethane, and 4-tert-butyl-4'-methoxydibenzoylmethane; Examples include octocrylene, 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate, 1-(3,4-dimethoxyphenyl)-4,4-dimethyl-1,3-pentanedione, cinoxate, methyl-O-aminobenzoate, 3-(4-methylbenzylidene)camphor, octyl triazone, diethylaminohydroxybenzoylhexyl benzoate, bisethylhexyloxyphenol methoxyphenyl triazine, and methylenebisbenzotriazolyltetramethylbutylphenol, and one or more selected from these may be contained in the composition.

[0036] The content of the (each) ultraviolet absorber in the composition of the present invention is 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the total weight of the composition, in order to avoid excessive absorption of ultraviolet rays contained in incident light.

[0037] The composition of the present invention may contain an ultraviolet scattering agent. An ultraviolet scattering agent refers to a substance that can reflect and scatter ultraviolet rays to protect the skin and the like from ultraviolet rays. Examples of ultraviolet scattering agent materials that can be used in the present invention include titanium oxide, zinc oxide other than component (A), iron oxide, zirconium oxide, and aluminum oxide. Examples of ultraviolet scattering agents include those obtained by microparticulating or compounding these materials. The ultraviolet scattering agent preferably contains one or more types selected from titanium oxide and zinc oxide other than component (A).

[0038] The titanium oxide and zinc oxide used as the UV scattering agent may be the titanium oxide and zinc oxide commonly used in cosmetics. Preferably, the titanium oxide and zinc oxide used in the composition have better dispersibility, for example, those whose surfaces have been subjected to a known surface treatment, specifically a hydrophobic treatment, as necessary.

[0039] Examples of surface treatment methods include silicone treatment with methylhydrogenpolysiloxane, methylpolysiloxane, etc.; fluorine treatment with perfluoroalkyl phosphate ester, perfluoroalcohol, etc.; amino acid treatment with N-acylglutamic acid, etc.; alkylalkoxysilane treatment with octyltriethoxysilane, octyltrimethoxysilane, etc.; lecithin treatment; metal soap treatment; fatty acid treatment; alkyl phosphate ester treatment, etc. Of these, zinc oxide whose surface has been treated with silicone is preferably used.

[0040] The silicones used in the surface treatment are not limited, and examples thereof include various silicone oils such as methylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, methylcyclopolysiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, octamethyltrisiloxane, tetradecamethylhexasiloxane, dimethylsiloxane-methyl(polyoxyethylene)siloxane-methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane-methyl(polyoxyethylene)siloxane copolymer, dimethylsiloxane-methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane-methylcetyloxysiloxane copolymer, and dimethylsiloxane-methylstearoxysiloxane copolymer. Methylhydrogenpolysiloxane and methylpolysiloxane are preferred.

[0041] The content of the (each) ultraviolet scattering agent contained in the composition of the present invention is 30% by weight or less, preferably 20% by weight or less, more preferably 15% by weight or less, and even more preferably 10% by weight or less, of the total composition in order to avoid excessive scattering of ultraviolet rays contained in incident light.

[0042] (D) Oil The composition of the present invention contains an oil. The oil refers to a hydrophobic substance that is a component of the composition of the present invention and undergoes phase separation from water. The oil that can be used in the present invention is not particularly limited and includes, for example, at least one of hydrocarbon oils, ester oils, silicone oils, liquid oils, solid oils, and higher alcohols.

[0043] Examples of hydrocarbon oils include liquid paraffin, tetraisobutane, hydrogenated polydecene, olefin oligomer, isododecane, isohexadecane, squalane, and hydrogenated polyisobutene.

[0044] Examples of ester oils include diisopropyl sebacate, octyl palmitate, cetyl isooctanoate (cetyl 2-ethylhexanoate), triethylhexanoin, neopentyl glycol dicaprate, triisostearin, diisostearyl malate, PPG-3 dipivalate, di-2-ethylhexyl succinate, 2-ethylhexyl 2-ethylhexanoate, polyglyceryl-6 octacaprylate, and tri(caprylic / capric)glyceryl.

[0045] Examples of silicone oils include dimethicone, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane.

[0046] Examples of liquid oils include avocado oil, camellia oil, macadamia nut oil, mink oil, olive oil, castor oil, jojoba oil, triglycerin, and glycerin trioctanoate.

[0047] Examples of solid fats and oils include coconut oil, hardened coconut oil, palm oil, beef tallow, mutton tallow, Japan wax, and hardened castor oil.

[0048] Examples of higher alcohols include isostearyl alcohol, oleyl alcohol, and copolymers of butylene glycol and propylene glycol (for example, PBG / PPG-9 / 1 copolymer).

[0049] The total oil content of the composition of the present invention is 10% by weight or more, preferably 15% by weight or more, more preferably 20% by weight or more, and even more preferably 25% by weight or more, based on the total weight of the composition.

[0050] (optional ingredient) The composition of the present invention can be appropriately blended with various ingredients as long as the effects of the present invention are not adversely affected. Examples of the various ingredients include additives that are typically blended into cosmetics, such as clay minerals (dimethyl distearyl ammonium hectorite, etc.), powders (polymethyl methacrylate, crosslinked silicone / network silicone block copolymers, silica, talc including hydrophobized talc, starch such as corn starch, polyurethane including hydrophobized polyurethane, etc.), chelating agents, fragrances, moisturizers (glycerin, dipropylene glycol, etc.), preservatives, oil phase solidifying agents (sucrose tetrastearate triacetate, dextrin palmitate, palmitic acid, (behenic acid / eicosanedioic acid) glycol, etc.), and the like. Examples of the surfactants include: lysel, N-lauroyl L-glutamic acid dibutylamide, polyamide-8, etc.; anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, moisturizers, water-soluble polymers, film-forming agents such as silicone-modified polysaccharides, sequestering agents, lower alcohols, polyhydric alcohols, various extracts, sugars, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, vitamins, water-soluble agents applicable to pharmaceuticals, quasi-drugs, cosmetics, etc.; antioxidants, buffers, antioxidant aids, propellants, organic powders, pigments, dyes, coloring matter, water, acid components, alkaline components, etc. These optional components can be blended appropriately in the oil phase and the aqueous phase. Furthermore, to enhance the effects of the present invention, other cell activators, etc. may be contained or used in combination.

[0051] One embodiment of the composition of the present invention is a water-in-oil composition. The water-in-oil composition of the present invention can be produced according to a conventional production method. Specifically, the composition of this embodiment is obtained by the following procedure. That is, an ultraviolet absorber, an ultraviolet scattering agent, and other oily components are mixed together to prepare an oil phase, and if dispersing in the oil phase, (A) an ultraviolet wavelength conversion substance and (B) a dispersant are mixed in. Next, other water-soluble components are mixed together as appropriate to prepare an aqueous phase, and if dispersing in the aqueous phase, (A) an ultraviolet wavelength conversion substance and (B) a dispersant are mixed in. The aqueous phase is added to the oil phase and stirred to obtain the composition.

[0052] One embodiment of the composition of the present invention is a water-in-oil composition containing powders, such as polymethyl methacrylate, crosslinked silicone / network silicone block copolymers, silica, talc including hydrophobized talc, starch such as corn starch, and polyurethane including hydrophobized polyurethane. The water-in-oil composition containing the powder of the present invention can be produced according to a conventional production method.

[0053] The composition of the present invention includes compositions used in sunscreen cosmetics such as makeup bases and sunscreen creams, etc. The formulation may be, for example, emulsions, creams, etc.

[0054] The composition of the present invention can be used by applying, preferably coating, to skin, particularly skin excluding hair, preferably the face, body, hands, feet, etc. For example, applying, preferably coating, the composition of the present embodiment to skin not only protects against ultraviolet rays and suppresses adverse effects on the skin, but also activates skin cells to give the skin a natural and desirable appearance. [Example]

[0055] The present invention will now be described in more detail with reference to examples, although the present invention is not limited to these examples.

[0056] Experiment 1: Cell activation effects of various ultraviolet wavelength conversion substances Experiment 1-1: Preparation of ultraviolet wavelength conversion material The ultraviolet wavelength converting material was prepared as follows. (1) B-Phycoerythrin B-phycoerythrin was obtained from the extract of Porphiridium Cruentum, and its absorption spectrum had a peak wavelength at 305 nm, and its emission spectrum had peak wavelengths at 570 nm and 610 nm. (2) C-Phycocyanin C-phycocyanin was obtained from Spirulina platensis extract, and its absorption spectrum had a peak wavelength at 350 nm, and its emission spectrum had peak wavelengths at 640 nm and 700 nm. Linablue manufactured by DIC Corporation was used. (3) Zinc oxide phosphor Lumate G manufactured by Sakai Chemical Industry Co., Ltd. was used. Lumate G is a zinc oxide phosphor in which ZnO is doped with a sulfur-containing compound as described in International Publication No. 2018 / 004006, and its absorption spectrum has a peak wavelength at 365 nm, and its emission spectrum has a peak wavelength at 510 nm. (4) Magnesium titanate phosphor Lumate R manufactured by Sakai Chemical Industry Co., Ltd. was used. Lumate R is a magnesium titanate phosphor in which MgTiO3 is doped with manganese, and its absorption spectrum has a peak wavelength at 365 nm, and its emission spectrum has a peak wavelength in the 660 to 680 nm band. The ultraviolet wavelength conversion materials (1) and (2) were dissolved in water to prepare solutions with concentrations of 1% and 5%. The ultraviolet wavelength conversion materials (3) and (4) were dispersed in alcohol to prepare 5% and 10% dispersions.

[0057] Experiment 1-2: Preparation of cell samples The cell samples were prepared as follows. 1. Human skin fibroblasts and human skin keratinocytes purchased from Kurabo Co., Ltd. Cell suspensions (1 mL) stored in liquid nitrogen were thawed in a water bath (37°C) until a small ice pellet remained, and then diluted with 9 mL of warm medium. 2. The dilutions were mixed gently and then transferred to T75 flasks and incubated overnight at 37°C. 3. The next day, the medium was replaced with 10 mL of fresh medium. 4. The medium was changed periodically (once every two days for fibroblasts, once every two to three days for keratinocytes) to allow cell growth to continue. During this time, the cells were observed under a microscope to confirm that they were growing with the correct morphology. 5. When the cells reached approximately 80% confluence, they were passaged by washing the cells once with 10 mL of warm PBS, adding 5 mL of warm trypsin to a T75 flask, covering the bottom of the flask with the trypsin solution, leaving it at room temperature for 1 minute, and then aspirating the solution. 6. The flask was placed in a 37°C oven for a maximum of 2 minutes for fibroblasts and 7 minutes for keratinocytes. The cells were observed under a microscope to confirm that they were small and oval. 7. The side of the T75 flask was then gently tapped to release the cells, and the cells were observed under a microscope to confirm that they were moving freely. 8. The fibroblasts were resuspended in 5 mL of warm FGM (containing 10% serum) and transferred to a sterile 50 mL Falcon tube. The flask was rinsed with an additional 5 mL of warm FGM and added to the Falcon tube to ensure all cells were transferred. 9. The cells were centrifuged at 10,000 rpm for 5 minutes (4°C) and the supernatant was removed, being careful not to disturb the cell pellet. 10. Depending on the cell type, fibroblasts were 2 x 10 4 cells / well (500 μL), keratinocytes: 4 × 10 4 The cells were resuspended in FGM or KGM at a concentration of 500 μL per well and plated in 24-well plates. 11. Cells were seeded in 24-well plates and grown until they reached 60-70% confluence (depending on the type of experiment) by changing the medium periodically (every 2 days for fibroblasts, every 2-3 days for keratinocytes). (Note: Fibroblasts were grown at 2 × 10 4 If the cell density is 1 × 10 cells / well, the desired confluency should be reached in 24 hours. 4 If the density is low, such as 100 cells / well, it will take 48 hours for the fibroblasts to reach the desired confluency. 12. 24 hours before irradiation, the medium was changed to supplement-free medium (for keratinocytes) or medium containing low concentrations of serum (0.5% FCS) (for fibroblasts).

[0058] Experiment 1-3: UV irradiation 1. The solar simulator was turned on and the lamp warmed up at least 30 minutes before irradiation. The solar simulator was set to use the UG11 filter, which passes only UVB and blocks other wavelengths. The UV light that passed through the UG11 filter had a peak wavelength between 300 nm and 385 nm. 2. The temperature control plate was turned on and set to 33°C. 3. The cells prepared in Experiment 1-2 were washed once with warm PBS. 4. Add 0.5 mL of warmed Martinez solution (145 mM NaCl, 5.5 mM KCl, 1.2 mM MgCl2.6H2O, 1.2 mM NaH2PO4.2H2O, 7.5 mM HEPES, 1 mM CaCl2, 10 mM D-glucose) to each well. 5. As shown in Figure 1, the cell wells were placed on a plate, and 0.4 ml of the solution containing the ultraviolet wavelength conversion substances (1) to (4) prepared in Experiment 1-1 was poured into each well of a 24-well plate on top of that, and the plate was placed so as to cover the wells containing the cells. This was done so that the solution of the ultraviolet wavelength conversion substance did not come into direct contact with the cell solution, and UV light was irradiated onto the cell solution through the solution of the ultraviolet wavelength conversion substance. 6. The total is 100mJ / cm 2 As controls, we prepared a sample in which the cells were directly irradiated with UV light without placing a plate of UV wavelength conversion material on the cell well, and a sample in which the cells were cultured in the dark without being irradiated with UV light. 7. After irradiation, Martinez was replaced with warmed KGM (without supplements) or FGM (containing 0.5% FCS), and the plates were returned to a 37°C incubator.

[0059] Experiment 1-4: Measurement of cell activity After Experiments 1-3, the cells were kept in an incubator for 48 hours and the activity was measured by the following method. 1. 10% Alamar Blue was added to the medium (KGM medium without supplements or FGM medium containing 0.5% FCS) and warmed to 37°C (the solution was kept in the dark). 2. The medium in the wells was replaced with 500 μL of the above 10% Alamar Blue solution, and the plate was returned to the incubator at 37°C for approximately 3 hours. Control wells were also kept in the incubator. These solutions were kept in the dark to protect them from light. 3. After 3 hours, 100 μL aliquots were taken and transferred to black 96-well plates. 4. Fluorescence measurements were taken at 544 nm / 590 nm using a fluorometer (OPwave+, Ocean Photonics).

[0060] The results are shown in Figure 2. When UV was irradiated, cell activity was reduced compared to the non-irradiated control. However, the activity of cells irradiated with UV through a UV wavelength conversion substance was increased compared to the non-irradiated control with all UV wavelength conversion substances. These results demonstrate that although UV irradiation reduces cell activity, the use of a UV wavelength conversion substance can suppress this reduction in cell activity.

[0061] Example 2: Effects of UV wavelength conversion substance concentration and UV intensity on cell activity Cell cultures were covered with plates containing solutions containing C-phycocyanin as a UV wavelength conversion substance at concentrations of 0%, 0.4%, and 2%, and the radiation intensity was measured at 0, 10, 25, 50, 75, and 100 mJ / cm. 2 The same method as in Experiment 1 was used, except that UV irradiation was performed at a dose of .

[0062] The results are shown in Figure 3. Without the use of an ultraviolet wavelength conversion substance, cell activity decreased as the amount of UV irradiation increased. However, the addition of 0.4% C-phycocyanin suppressed the decrease in cell activity even with UV irradiation, and the addition of 2% C-phycocyanin actually enhanced cell activity compared to the absence of UV irradiation. These results demonstrate that, although UV irradiation reduces cell activity, the use of an ultraviolet wavelength conversion substance not only inhibits the decrease in cell activity in a concentration-dependent manner, but also enhances it.

[0063] Example 3: Restoration of cell activity reduced by UV irradiation As shown in Figure 4, the irradiation dose was 400 mJ / cm without using ultraviolet wavelength conversion material. 2 After temporarily reducing cell activity by UV irradiation, the cell culture was covered with a plate containing a solution containing 0%, 0.4%, and 2% C-phycocyanin as a UV wavelength conversion substance, and the exposure was 0, 10, 25, 50, 75, 100, and 200 mJ / cm. 2 The same method as in Experiment 1 was used except that UV irradiation was continued until the dose reached .

[0064] The results are shown in Figure 5. It can be seen that even in cells whose activity had been reduced by UV irradiation without the use of an ultraviolet wavelength conversion substance, cellular activity was restored by UV irradiation using an ultraviolet wavelength conversion substance. Furthermore, this effect was equivalent to that at a 0.4% concentration of C-phycocyanin as at a 2% concentration, suggesting that even 0.4% C-phycocyanin has a sufficient cell activation effect. On the other hand, when UV irradiation was performed without the use of an ultraviolet wavelength conversion substance, cellular activity decreased in a UV dose-dependent manner.

[0065] The above results were shown for human skin fibroblasts, but similar results were also observed for keratinocytes (data not shown). These results demonstrate that UV wavelength conversion substances not only suppress the decline in cell activity caused by UV irradiation, but also have the effect of activating cells using UV light. Activation of skin cells is expected to prevent and improve wrinkles, age spots, skin aging, photoaging, etc.

[0066] From the above Examples 1 to 3, it was considered that the ultraviolet wavelength converting substance converts the wavelength of ultraviolet light, and the emitted visible light (fluorescence with a dominant wavelength of 500 nm to 700 nm) activates skin cells such as fibroblasts and keratinocytes. Therefore, various compositions containing the ultraviolet wavelength converting substance were produced below, and the amount of fluorescence emitted when irradiated with ultraviolet light was evaluated.

[0067] The amount of fluorescence was measured by applying the composition to an S plate (see Patent No. 4453995) at a concentration of 2 mg / cm 2 The composition was coated on a substrate at a temperature of 100°C and dried to prepare a coating film. The resulting coating film was irradiated with ultraviolet light of a predetermined wavelength, and the fluorescence integrated value in the predetermined wavelength range was measured using a spectrofluorometer RF-5300PC (Shimadzu Corporation). When the ultraviolet wavelength conversion substance was Lumate G, the coating was irradiated with ultraviolet light of 365 nm, and the fluorescence integrated value from 400 to 600 nm was measured in the same manner. When the ultraviolet wavelength conversion substance was Lumate R, the coating was irradiated with ultraviolet light of 340 nm, and the fluorescence integrated value from 550 to 800 nm was measured in the same manner. When the ultraviolet wavelength conversion substance was LinaBlue, the coating was irradiated with ultraviolet light of 350 nm, and the fluorescence integrated value from 550 to 800 nm was measured in the same manner.

[0068] Example 4: Function of ultraviolet wavelength conversion material in the presence of ultraviolet absorber / ultraviolet scattering agent Compositions (Formulation Examples U1 and U2) having the compositions shown in Table 1 were produced according to a conventional manufacturing method. Formulation Examples U1 and U2 contain a zinc oxide phosphor (Lumate G), which is an ultraviolet wavelength conversion substance, and Formulation Example U2 further contains an ultraviolet absorber (octocrylene, ethylhexyl salicylate, and homosalate) and an ultraviolet scattering agent (fine particle zinc oxide). Although the fluorescence integrated value of Formulation Example U1 was 25,624 and that of Formulation Example U2 was 3,570, which was lower, it was found that the ultraviolet wavelength conversion substance still had a wavelength conversion function even in the coexistence of an ultraviolet absorber and an ultraviolet scattering agent.

[0069] [Table 1]

[0070] Example 5: Effect of ultraviolet wavelength conversion material zinc oxide phosphor Compositions (Formulation Examples G1 to G6) with the compositions listed in Table 2 were produced according to a conventional manufacturing method. All formulation examples contained a zinc oxide phosphor (Lumate G), an ultraviolet wavelength conversion substance. The integrated fluorescence values ​​for formulation examples G1 to G6 were 669, 2230, 4273, 16116, 23515, and 43316, respectively, demonstrating that the zinc oxide phosphor possessed a dose-dependent wavelength conversion function when included in the composition.

[0071] [Table 2]

[0072] Example 6: Effect of magnesium titanate phosphor as ultraviolet wavelength conversion material Compositions (formulation examples R1 to R5) with the compositions listed in Table 3 were produced according to a conventional manufacturing method. All formulation examples contain a magnesium titanate phosphor (Lumate®), an ultraviolet wavelength conversion substance. The integrated fluorescence values ​​for formulation examples R1 to R5 were 4986, 7537, 5797, 5488, and 8746, respectively, demonstrating that the magnesium titanate phosphor possesses a dose-dependent wavelength conversion function even when included in the composition.

[0073] [Table 3]

[0074] Example 7: Effect of ultraviolet wavelength conversion substance C-phycocyanin The compositions (formulation examples L1 to L5) listed in Table 4 were produced according to a conventional manufacturing method. All formulation examples contained C-phycocyanin (LinaBlue), an ultraviolet wavelength conversion substance. The integrated fluorescence values ​​for formulation examples L1 to L5 were 6308, 11937, 9287, 5608, and 3946, respectively. This indicates that C-phycocyanin retains wavelength conversion function even when included in the composition, and that the ultraviolet wavelength conversion effect exhibited a bell-shaped dose dependence, with LinaBlue concentrations of 0.5% to 3% being optimal.

[0075] [Table 4]

[0076] Example 8: Effect of dispersant PEG-10 dimethicone Compositions (Formulation Examples D1 to D4) with the compositions listed in Table 5 were produced according to a conventional manufacturing method. All formulation examples contained a zinc oxide phosphor (Lumate G), an ultraviolet wavelength conversion substance. The integrated fluorescence values ​​for formulation examples D1 to D4 were 3570, 4015, 5657, and 6500, respectively. This indicates that the dispersant PEG-10 dimethicone dose-dependently enhances the wavelength conversion function of the zinc oxide phosphor, and that combining it with another dispersant, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, further enhances the wavelength conversion function.

[0077] [Table 5] Example 9: Effect of Combinations of Dispersants Compositions (Formulation Examples M1 to M10) with the compositions listed in Table 6 were prepared according to a conventional manufacturing method. Each formulation contained the zinc oxide phosphor Lumate G, an ultraviolet wavelength conversion material. The integrated fluorescence values ​​for Formulation Examples M1 to M10 were 4294, 5685, 6779, 7412, 7608, 7016, 4309, 7305, 3633, and 1531, respectively. This indicates that the wavelength conversion function of the zinc oxide phosphor can be enhanced by combining the dispersant PEG-10 dimethicone with bis-butyl dimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, or carboxydecyl trisiloxane, compared to PEG-10 dimethicone alone.

[0078] [Table 6-1] [Table 6-2] Example 10: Effect of powder Compositions (Formulation Examples P1 to P7) with the compositions listed in Table 7 were produced according to a conventional manufacturing method. All formulation examples contained zinc oxide phosphor (Lumate G), an ultraviolet wavelength conversion substance. The integrated fluorescence values ​​for formulation examples M1 to M10 were 19133, 21805, 19486, 23191, 21689, 21788, and 22552, respectively. This indicates that the inclusion of various powders in the compositions did not suppress the wavelength conversion function of the zinc oxide phosphor, while silica powder, for example, enhanced the wavelength conversion function of the zinc oxide phosphor. This suggests that water-in-oil compositions containing powders can also be produced as cell activators.

[0079] [Table 7]

[0080] Example 11: Effect on cytochrome c content In Examples 1 to 3, it was found that wavelength-converted visible light enhances the reduction ability due to electron acceptance from the mitochondrial respiratory chain in the AlamarBlue assay. Cytochrome c is a molecule involved in the mitochondrial electron transport system and plays an important role in the production of the reducing agent NDH molecule. Therefore, we next examined whether the composition of the present invention affects the intracellular concentration of cytochrome c in cells.

[0081] The composition of the present invention was applied and dispensed at 0.1 g / well onto a 24-well plate and allowed to dry. Human skin fibroblasts (ScienCell Research Lab. #2320) were added to the 24-well plate at 1 x 10 5Cells were seeded at a density of 1000 cells / well and cultured in DMEM medium (Thermo Fisher, #11965-092) for 3 days. After washing with PBS, 1 mL of PBS was added. The 24-well plate containing the dried composition was placed on top of the 24-well plate containing the cells, and irradiated for 40 minutes at maximum power using an artificial solar lamp (Serric, XC-500BF) from a distance of approximately 70 cm. All cell plates were placed on a heat storage material at 20°C to prevent temperature rise. After the irradiation time, the PBS was removed, and 0.3 mL of cell extract (RIPA buffer: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% (w / v) sodium deoxycholate, 0.1% (w / v) SDS, 1.0% (w / v) NP-40 substitute, 1 mM PMSF) was added. The cells were completely lysed by pipetting. The cell lysate was centrifuged at 10,000×g for 10 minutes at 4°C, and cytochrome c in the supernatant was measured (Proteintech Group, KE00079).

[0082] No effect was observed on the appearance of the cells before and after sunlight exposure. The cytochrome c content in cells without the composition was 3782 pg / mL, while the cytochrome c contents of formulations M4 and M5, which had a high UV wavelength conversion function, were 5150 pg / mL and 5448 pg / mL, respectively, demonstrating that the composition increased the amount of cytochrome c in the cells.

[0083] The above has described embodiments of the composition of the present invention. However, the present invention is not limited to these, and can be modified as appropriate within the scope of the invention.

Claims

[Claim 1] (A) an ultraviolet wavelength conversion substance, (B) a dispersant, (C) an ultraviolet absorber and / or an ultraviolet scattering agent, (D) an oil component, and a powder, the ultraviolet wavelength converting substance (A) contains at least one selected from the group consisting of phycobiliprotein, vitamin A, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, a zinc oxide phosphor, and a magnesium titanate phosphor; the (B) dispersing agent comprises a combination of PEG-10 dimethicone and one or more selected from the group consisting of bisbutyl dimethicone polyglyceryl-3, PEG9-polydimethylsiloxyethyl dimethicone, lauryl PEG9-polydimethylsiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, and carboxydecyl trisiloxane; the powder contains one or more selected from the group consisting of polymethyl methacrylate, silica, talc, starch, and polyurethane, and the blending amount of the powder is 5% by weight or less; composition.

Images